Sonic Healthcare Limited (ASX:SHL) has disclosed the issue of 581,322 unquoted performance rights on 19 November 2026 under its Performance Rights Plan, with grants made to key management personnel including the Managing Director and Finance Director, as well as non-KMP employees, all at a nil exercise price.

Key Points

  • 581,322 performance rights (ASX security code: SHLAZ) were issued on 19 November 2026 at nil exercise price under the Sonic Healthcare Performance Rights Plan.
  • 125,071 performance rights were granted to the Managing Director and Finance Director as long-term incentive components of their remuneration through to the 2029 financial year, following shareholder approval at the 2026 AGM.
  • Key management personnel James Pacey Newcombe received 87,456 performance rights and Christopher David Wilks received 37,615 performance rights.
  • 450,804 performance rights were granted to non-KMP employees, exercisable from 19 November 2029 until 19 November 2031, subject to performance conditions.
  • Following the issue, total unquoted SHLAZ performance rights on issue stand at 853,430, with 494,237,953 ordinary fully paid shares quoted on ASX.

Performance Rights Grant Details and Vesting Terms

According to the filing, each performance right, upon vesting and exercise in accordance with plan terms, will entitle the holder to one fully paid ordinary share in Sonic Healthcare Limited. The majority of the performance rights — 450,804 granted to non-KMP — are exercisable from 19 November 2029 until an expiry date of 19 November 2031, subject to the satisfaction of performance conditions. A further 5,447 performance rights were granted to non-KMP employees and are exercisable from 1 March 2027 until 1 October 2027. Holders of these latter rights will be restricted from disposing of shares allocated on exercise until 1 October 2027.

Key Management Personnel Allocations

The filing identifies two key management personnel who received performance rights as part of this grant. James Pacey Newcombe was issued 87,456 performance rights, registered in his own name. Christopher David Wilks received 37,615 performance rights, registered to Mr Christopher David Wilks. Together, these two KMP allocations total 125,071 performance rights, issued as the long-term incentive component of their remuneration through to the 2029 financial year. The filing states these grants were made pursuant to shareholder approval received at the 2026 Annual General Meeting.

Securities on Issue Following the Grant

Following the issue of the 581,322 performance rights, Sonic Healthcare's total unquoted SHLAZ performance rights on issue stand at 853,430. The company also has 28,937,237 unquoted options on issue under the SHLAK code. Quoted ordinary fully paid shares on ASX total 494,237,953. The filing states the performance rights were issued under an exception in Listing Rule 7.2, specifically exception 13, and therefore did not require securityholder approval under Listing Rule 7.1. The securities are not intended to be quoted on ASX.